Why Abbott Laboratories Will Keep Running in 2014

While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a closer look at particularly stock-shaking upgrades and downgrades -- just in case their reasoning behind the call makes sense.

What: Shares of Abbott Laboratories opened up slightly this morning after Morgan Stanley upgraded the health care giant from equal weight to overweight.

So what: Along with the upgrade, analyst David Lewis planted a price target of $45 on the stock, representing about 14% worth of upside to yesterday's close. While value investors might be turned off by the stock's surge since October, Lewis believes there's more room to run given Abbott's seemingly underappreciated growth prospects.

Now what: Morgan Stanley sees headwinds ahead for Abbott in the near term, but thinks that its long-term risk/reward trade-off is attractive at this point. "ABT's 40% emerging market revenue mix is largely unhedged, implying '13 FX moves could pressure 1H margins, in line with [Covidien ] and [Johnson & Johnson ] commentary," noted Lewis. "We are comfortable with the consensus '14 outlook for revenue growth >5% and EPS at $2.21/up 10%." With stock up about 10% over the past month alone, and trading at a forward P/E near 20, however, Fools might want to wait for a wider margin of safety before betting on it.

More compelling income opportunities

One of the dirty secrets that few finance professionals will openly admit is the fact that dividend stocks as a group handily outperform their non-dividend paying brethren. The reasons for this are too numerous to list here, but you can rest assured that it's true. However, knowing this is only half the battle. The other half is identifying which dividend stocks in particular are the best. With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor's portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.

The article Why Abbott Laboratories Will Keep Running in 2014 originally appeared on Fool.com.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Covidien and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story